Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Non-Current Assets (2016 - 2025)

Regenxbio has reported Non-Current Assets over the past 12 years, most recently at $171.8 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $171.8 million for Q4 2025, down 8.64% from a year ago — trailing twelve months through Dec 2025 was $750.0 million (down 11.79% YoY), and the annual figure for FY2025 was $171.8 million, down 8.64%.
  • Non-Current Assets for Q4 2025 was $171.8 million at Regenxbio, down from $193.2 million in the prior quarter.
  • Over the last five years, Non-Current Assets for RGNX hit a ceiling of $595.1 million in Q4 2021 and a floor of $171.8 million in Q4 2025.
  • Median Non-Current Assets over the past 5 years was $285.8 million (2023), compared with a mean of $323.3 million.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 236.26% in 2021 and later tumbled 42.73% in 2023.
  • Regenxbio's Non-Current Assets stood at $595.1 million in 2021, then decreased by 29.88% to $417.3 million in 2022, then plummeted by 42.73% to $239.0 million in 2023, then decreased by 21.34% to $188.0 million in 2024, then fell by 8.64% to $171.8 million in 2025.
  • The last three reported values for Non-Current Assets were $171.8 million (Q4 2025), $193.2 million (Q3 2025), and $207.3 million (Q2 2025) per Business Quant data.